Wide Ranks

AVTX

Avalo Therapeutics, Inc.

9.55

Top Statistics
Market Cap 99 M Forward PE -2.03 Revenue Growth 5.50 %
Current Ratio 1.42 Trailing PE 0.1011 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.6640 Enterprise / Revenue 25.24 Price To Sales Trailing12 Months 121.86
Profitability
Profit Margins 0.00 % Operating Margins -5165.06 %
Balance Sheet
Total Cash 81 M Total Cash Per Share 7.88 Total Debt 1 M
Total Debt To Equity 7.18 Current Ratio 1.42 Book Value Per Share 2.18
All Measures
Short Ratio 18.00 % Message Board Id finmb_145313032 Shares Short Prior Month 49242
Return On Equity -0.4252 City Rockville Uuid c39cf053-89ed-3335-9b81-3e09163c6ebf
Previous Close 9.99 First Trade Date Epoch Utc 1 B Book Value 2.18
Beta 1.03 Total Debt 1 M Volume 35841
Price To Book 4.39 Last Split Date 1 B Fifty Two Week Low 3.95
Total Cash Per Share 7.88 Total Revenue 820000 Shares Short Previous Month Date 1 B
Target Median Price 35.00 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -5165.06 % Target Mean Price 35.00 Net Income To Common -8135000
Short Percent Of Float 0.0009 Implied Shares Outstanding 10 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 58270 Average Volume10days 58270
Total Cash 81 M Next Fiscal Year End 1 B Revenue Per Share 0.3960
Held Percent Insiders 0.0586 Trailing PE 0.1011 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 9.99 Target Low Price 35.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 11.12 Open 9.99
Free Cashflow 39 M State MD Dividend Yield 0.00 %
Return On Assets -0.3064 Time Zone Short Name EST Trailing Eps 94.42
Day Low 9.31 Address1 540 Gaither Road Shares Outstanding 10 M
Price Hint 2 Target High Price 35.00 Website https://www.avalotx.com
52 Week Change -0.4315 Average Volume 37984 Forward Eps -4.70
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 136.60 %
Last Split Factor 1:240 Regular Market Day High 9.99 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 7.18 Fifty Two Week High 34.46
Day High 9.99 Shares Short 9775 Regular Market Open 9.99
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 25.24
Revenue Growth 5.50 % Shares Percent Shares Out 0.0009 Operating Cashflow -36778000
Currency USD Time Zone Full Name America/New_York Market Cap 99 M
Is_nasdaq_100 False Zip 20850 Quote Type EQUITY
Industry Biotechnology Long Name Avalo Therapeutics, Inc. Regular Market Day Low 9.31
Held Percent Institutions 0.6499 Current Price 9.55 Address2 Suite 400
Enterprise To Ebitda -0.6640 Financial Currency USD Current Ratio 1.42
Industry Disp Biotechnology Number Of Analyst Opinions 1 Country United States
Float Shares 5 M Two Hundred Day Average 10.61 Enterprise Value 20 M
Price To Sales Trailing12 Months 121.86 Forward PE -2.03 Regular Market Volume 35841
Ebitda -31167000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States.

The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.

It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases.

The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021.

Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.